VTE PREDICT is an online calculator that assists with the decision to whether stop or continue anticoagulation for venous thromboembolism (VTE) after initial treatment
considers individual risks of recurrence and bleeding
study by de Winter et al aimed to develop and externally validate models for predicting 5-year risks of recurrence and bleeding in patients with VTE without cancer who completed at least 3 months of initial treatment - used to estimate individual absolute benefits and harms of extended anticoagulation
considerations:
anticoagulant treatment is effective in reducing VTE recurrence risk but it is associated with a 1%-2% annual risk of major bleeding
risk of VTE recurrence is low (3% per year or less), if the VTE has been provoked by major transient risk factors (e.g. major surgery), and treatment discontinuation is recommended after 3 months
concluded that
VTE-PREDICT risk score estimates the risks of recurrent VTE and bleeding in patients with VTE who do not have active cancer and who have completed initial anticoagulant treatment
VTE-PREDICT risk score can be applied to estimate the absolute benefits and harms of extended anticoagulation for individual patients and support shared decision-making
de Winter MA et al; VTE-PREDICT study group. Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score. Eur Heart J. 2023 Apr 7;44(14):1231-1244. doi: 10.1093/eurheartj/ehac776. PMID: 36648242; PMCID: PMC1007939
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page